Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma

Area of Science:

• Oncolytic virotherapy
• Cancer gene therapy
• Hepatocellular carcinoma research

Background:

• Constitutive activation of Signal Transducer and Activator of Transcription 3 (STAT3) drives cancer cell proliferation and survival.
• Suppressor of Cytokine Signaling 1 (SOCS1) is a key negative regulator of STAT pathways, frequently silenced in cancers.
• SOCS1 is downregulated in hepatocellular carcinoma (HCC) due to hypermethylation.

Purpose of the Study:

• To investigate the potential of an oncolytic adenoviral vector (AdCN305-SOCS1) for delivering the SOCS1 gene to treat HCC.
• To evaluate the efficacy of AdCN305-SOCS1 in inhibiting STAT3 signaling and inducing apoptosis in HCC cells.

Main Methods:

• Utilized an oncolytic adenoviral vector (AdCN305-SOCS1) for targeted gene delivery of SOCS1 to HCC cells.
• Assessed SOCS1 expression, STAT3 phosphorylation, and downstream targets (survivin, cyclin D1, Bcl-xL, C-myc) post-infection.
• Evaluated the in vitro and in vivo cytotoxicity of AdCN305-SOCS1 in HCC models.

Main Results:

• AdCN305-SOCS1 selectively replicated in HCC cells, leading to SOCS1 overexpression.
• Infection with AdCN305-SOCS1 inhibited STAT3 phosphorylation and downregulated key oncogenic proteins.
• AdCN305-SOCS1 demonstrated significant cytotoxicity against HCC cells, inducing apoptosis both in vitro and in vivo.

Conclusions:

• Targeted delivery of SOCS1 via an oncolytic adenovirus effectively suppresses HCC progression.
• This approach offers a potential novel therapeutic strategy for hepatocellular carcinoma treatment.
• Restoring SOCS1 expression is a promising avenue for combating STAT3-driven cancers.